Phase III, Placebo-Controlled Trial of Three Doses of Citalopram for the Treatment of Hot Flashes: NCCTG Trial N05C9

PURPOSE: Up to 75% of women experience hot flashes, which can negatively impact quality of life. As hot flash physiology is not definitively understood, it cannot be assumed that effective agents represent class effects. Therefore, there is a continued need for rigorous evaluation to identify effect...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Barton, Debra L., LaVasseur, Beth I., Sloan, Jeff A., Stawis, Allen N., Flynn, Kathleen A., Dyar, Missy, Johnson, David B., Atherton, Pamela J., Diekmann, Brent, Loprinzi, Charles L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2010
Konular:
Original Reports
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2903326/
https://ncbi.nlm.nih.gov/pubmed/20498389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.26.6379
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller